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he Evolution of
hienopyridine Therapy
lopidogrel Duration,
iabetes, and Drug-Eluting Stents*
eung-Hyuk Choi, MD,*† Anand Prasad, MD,*†
otirios Tsimikas, MD, FACC*†
eoul, Korea; and San Diego, California
he widespread clinical application of coronary stents was
aralleled by another fundamental advance in adjunctive med-
cal therapy, namely the recognition of the critical role of the
latelet in stent thrombosis. During the early development of
are-metal stents (BMS), the use of prolonged heparin infu-
ion, dextran, aspirin, dipyridamole, and warfarin remained
uboptimal in preventing acute and subacute stent thrombosis.
he addition of thienopyridines to aspirin, along with optimal
tent deployment techniques, had reduced the incidence of
tent thrombosis to an acceptably low level (1% to 2%).
See page 2220
The introduction of drug-eluting stents (DES) was heralded
y euphoria when early reports suggested near zero percent
estenosis. However, pre-clinical DES studies had suggested
ess-complete vessel healing, and the initial recommendation
as to increase the use of dual antiplatelet therapy to 3 to 6
onths. This initial excitement was significantly tempered by
he realization of late (1 year) stent thrombosis and poten-
ially of death and myocardial infarction (MI). This was
ocumented by a variety or sources, including the Food
nd Drug Administration (FDA); case reports (1); and
linical studies and registries such as BASKET-LATE
Basel Stent Cost-Effectiveness Trial—Late Thrombotic
vents) (2), SCAAR (Swedish Coronary Angiography and
ngioplasty Registry) (3), and the Denmark registries (4).
ubgroup analyses demonstrated that stent thrombosis was
ore prevalent in several clinical (diabetes, older age, renal
ailure) and angiographic subsets (ostial, bifurcation, over-
apping stents, prior brachytherapy) and was particularly
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the *Department of Medicine, Samsung Medical Center, Sungkyunkwann
niversity School of Medicine, Seoul, Korea; and the †Division of Cardiology,
niversity of California San Diego, San Diego, California.otentiated by clopidogrel withdrawal (5). For example,
iroldi et al. (6) showed that stent thrombosis occurred on
verage after 13 days if clopidogrel was discontinued within the
rst 6 months of stent placement. However, if clopidogrel was
iscontinued after 6 months of stent placement, stent throm-
osis occurred on average 90 days later, suggesting different
athophysiological mechanisms of subacute and late stent
hrombosis.
The rapid penetration of DES use (near 90%) resulted in
ignificant application in “off-label” indications, which are
ssociated with increased adverse events for both DES and
MS (7). Interestingly, long-term follow-up of patients in
andomized trials has not shown an increased cumulative risk
f death/MI, but some landmark analyses censoring events
efore 6 months have shown an additional 0.1% to 0.5% risk of
ES thrombosis starting at 6 months after stent deployment
8,9). These findings led to major debate regarding the clinical
sefulness of DES in scientific circles, regulatory agencies, and
he public, leading to a reassessment of the appropriate indi-
ations for DES, which hitherto had only shown a decrease in
arget vessel revascularization (TVR) but not death and MI
10). In a case of the perfect storm, concurrent publication of
he COURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) trial intensified the
ebate of the role of percutaneous coronary intervention (PCI)
n stable angina, leading to a downward re-equilibration of
ES use (11).
Compared with BMS, DES resulted in markedly reduced
eointima formation but also in delayed endothelialization,
ore inflammation, hypersensitivity, thrombus formation, and
utward remodeling, which might prolong the window of
ulnerability to stent thrombosis (12). With increasing concern
bout late stent thrombosis, the FDA along with the American
eart Association/American College of Cardiology (AHA/
CC) and recently updated PCI guidelines (13) have empiri-
ally suggested at least 1 year of clopidogrel in patients not at
igh risk for bleeding, making this a Class I, Level of Evidence:
indication. Clopidogrel use beyond 1 year was designated a
lass IIb, Level of Evidence: C indication.
In this issue of the Journal, Brar et al. (14) provide valuable
nformation regarding the duration of clopidogrel therapy after
ES. They evaluated a consecutive series of 749 diabetic
atients for 18 months who underwent first-time PCI with
ither DES or BMS at a pre-paid system with near complete
ccess to the number of clopidogrel prescriptions filled, dose,
nd number of pills dispensed. Increased duration of clopi-
ogrel use was associated with a significantly lower incidence of
eath and MI (3.2%, 9.4%, and 16.5% for clopidogrel duration
9 months, 6 to 9 months, and 6 months, respectively) in
oth the DES and BMS groups. Furthermore, this finding
ersisted even when data in the first 6 months were censored,
onsistent with a durable effect. In a secondary analysis, the
ncidence of death and MI did not differ by stent type, but this
nalysis is likely underpowered. This study also lacks data on
ondiabetic patients, and this system of health care delivery is
n
D
p
r
e
E
d
a
r
i
T
e
a
o
a
i
r
i
fi
r
a
s
D
F
D
l
o
c
r
s
p
c
i
m
p
i
g
f
p
a
l
a
o
t
w
c
e
R
V
9
E
R
1
1
1
1
1
1
1
1
1
1
2229JACC Vol. 51, No. 23, 2008 Choi et al.
June 10, 2008:2228–9 Editorial Commentot representative of that for most patients who are receiving
ES in the U.S. Nonetheless, it provides important data in a
atient subgroup that is at highest risk of stent thrombosis,
estenosis, progression of atherosclerosis, and new thrombotic
vents (15).
These data are consistent with and extend the findings of
isenstein et al. (16), who also showed that extended clopi-
ogrel use was associated with lower adjusted rates of death
nd MI. In that study, adjudication of clopidogrel use was less
eliable, because it was based on patient self-report and the
ncidence and outcomes in diabetic patients was not reported.
hese 2 studies in composite provide reassuring data that
xtended clopidogrel use is associated with improved outcomes
nd substantiate the AHA/ACC recommendation for 1 year
f clopidogrel in patients receiving DES. Both of these studies
re limited by the observational nature, the presence of several
mportant baseline differences in groups, lack of reporting on
ates of major bleeding, and undeniable physician selection bias
n choosing the duration of clopidogrel. Therefore, these
ndings need to be validated in randomized clinical trials.
The initial reports of increased death and MI in DES
egistries have recently been counterbalanced by several new
nalyses (Ontario, Massachusetts, and New York registries)
howing at least similar if not better overall clinical outcomes of
ES versus BMS with continued reduction in TVR (17).
urthermore, the initial worse outcomes in patients receiving
ES in the SCAAR registry have not been confirmed in
onger-term follow-up. Finally, data from a Medicare database
f over 75,000 patients suggest a mortality benefit of DES
ompared with BMS (18). The reasons for these disparate
esults are not yet clear but might reflect better patient
election, increased use of BMS in patients who cannot sustain
rolonged clopidogrel treatment, and increasing duration of
lopidogrel therapy. However, it is evident that significant
mprovements must be made in reducing restenosis in a safer
anner and in a manner that does not hold patients and
hysicians captive to long-term thienopyridine use. These
nclude newer generation of stents with low risk of thrombo-
enesis, novel pharmacologic therapies, and identification of
actors mediating platelet resistance, particularly in diabetic
atients (19). The continued evolution of thienopyridine ther-
py for stent thrombosis has reached a crescendo of “treat as
ong as the patient can tolerate it,” and it will likely change
gain as new data are published, particularly with evolving data
n the risk of bleeding with long-term thienopyridine use. In
he meantime, in patients who have already received DES and
ho are not at high risk of bleeding, it seems prudent to
ontinue dual antiplatelet therapy indefinitely until new data
merge demonstrating otherwise.
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